Selective delivery of adjuvant chemotherapy to healthier patients
Publication date: Available online 16 February 2020Source: The Annals of Thoracic SurgeryAuthor(s): Chadrick E. Denlinger, Barry C. Gibney
After initial efforts at heart transplantation (HT) in patients with light chain amyloidosis were fraught with poor outcomes, emerging experience with modern chemotherapy regimens has led to a major improvement in outcomes in select centers. Given the systemic nature of the disease and the added immunosuppression in the form of chemotherapy, this study sought to analyze if AL patients undergoing HT had a higher burden of readmissions and infections non-amyloid heart transplant patients.
AbstractTreatment options for patients with advanced gastric cancer (AGC) are limited. One approach to improving survival in patients with AGC is to optimize the available agents via sequential therapy. However, clinical trial reports of first-line chemotherapy indicate that elderly patients and patients with massive ascites are less likely to receive subsequent lines of therapy. In addition, clinical trials of second- and third-line chemotherapy generally exclude these two patient populations because they are likely to have poor performance status and additional issues that are difficult to manage. Good patient management...
The objective of this study was to analyze those risk factors of CINV through a systematic literature review.MethodsWe searched MEDLINE to identify articles that addressed patient-related risk factors of CINV through clinical studies.ResultsA total of 49 articles were selected for this study. A total of 28 patient-related risk-factors that significantly impact the risk of CINV were documented. Three factors are demographically related, 17 factors are intrinsic in nature and innate to patient's physiology or influenced by physiology, and eight factors are extrinsic in nature. At least five studies identified seven risk fact...
ConclusionsOur study reveals the need for targeted patient ‐education about the benefits and limitations of follow‐up. In order to meet increasing costs of cancer care, individualized follow‐up procedures adjusted to risk of recurrence and late‐effects in cervical cancer survivors are warranted.
We’re tackling a few urgent questions from parents in this time of coronavirus and COVID-19. Are you wondering if babies and children should continue to have vaccines on schedule? Thinking about how to manage regular medical appointments, and which situations require in-person visits to a pediatric practice? Read on. Should parents take babies for initial vaccines right now? What about toddlers and older children who are due for vaccines? The answer to this question is going to depend on many factors, including what your doctor’s office is offering. As with all health care decisions, it comes down to weighing r...
Conclusion: This is the first prospective study demonstrating the safety and efficacy of a combined DIEP flap with vascularized inguinal lymph node transfer and lymphovenous anastomosis, which may be superior to lymph node transfer alone. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
Chemotherapy for breast cancer negatively impacts a woman ’s fertility after treatment — especially women with a cancer-causing BRCA mutation.
Purpose: Synchronous chemotherapy with mitomycin C and 5-FU with radiotherapy may have an additional benefit over radiotherapy alone . We looked into the rate of recurrence and median overall survival between these two groups of patients.
Purpose: The use of FDG PET has become more readily available over the past 15 years. It can be used to aid initial staging of testicular tumours and also assess the response to treatment in the metastatic setting, especially as residual masses are frequently seen after chemotherapy. There have been some recent concerns that FDG PET used to assess for residual disease may have a low positive predictive value . A retrospective audit was carried out to look at the performance of FDG PET in seminoma patients treated at the Edinburgh Cancer Centre.
Purpose: The STAMPEDE trial has recently shown a benefit in overall survival by irradiating the prostate of patients with newly diagnosed metastatic prostate cancer . This benefit was only shown in patients with low burden of metastatic disease, as per the CHAARTED criteria . The current standard of care for these patients is androgen deprivation therapy ± docetaxel chemotherapy and radiotherapy to symptomatic areas of disease if required. The aim of this audit is to determine the potential number of men with low burden of metastatic disease who may require additional radiotherapy.